Tafasitamab (Minjuvi)


 CADTH recommends that Minjuvi, in combination with lenalidomide, not be reimbursed by public drug plans for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) otherwise specified, including DLBCL arising from low grade lymphoma, who are eligible autologous stem cell transplant (ASCT).
 The clinical evidence reviewed was strong enough to show whether Minjuvi lenalidomide benefits patients R/R DLBCL. It is known if would lead better outcomes compared currently available treatments.
 Patients identified a need treatments prolong survival and remission, control disease symptoms, improve health-related quality life (HRQoL), have fewer side effects current therapies. clear meets these needs.